# Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa

> **NCT03638830** · PHASE2 · COMPLETED · sponsor: **Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation** · enrollment: 777 (actual)

## Conditions studied

- Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa
- Pseudomonas Aeruginosa
- Pseudomonas Infections
- Urinary Tract Infections

## Interventions

- **DRUG:** Ftortiazinon (tablets 300 mg) 1/2 dose +placebo+ Maxipim
- **DRUG:** Ftortiazinon (tablets 300 mg) full dose + Maxipim
- **OTHER:** placebo+Maxipim

## Key facts

- **NCT ID:** NCT03638830
- **Lead sponsor:** Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-17
- **Primary completion:** 2022-11-23
- **Final completion:** 2022-11-23
- **Target enrollment:** 777 (ACTUAL)
- **Last updated:** 2025-06-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03638830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03638830, "Safety and Efficacy Study of Ftortiazinon in the Treatment of Patients With Complicated Urinary Tract Infections Caused by P. Aeruginosa". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03638830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*